Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Rawan Faramand, Liora M. Schultz et al.|Blood Advances|2025Cited by 15
S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDYVéronique Minard‐Colin, Birgit Burkhardt, Sara Napolitano et al.|HemaSphere|2022Cited by 5
Liberalizing Requirements for Hospital Proximity Post-CD19 CAR for Children with Low Burden B-ALL at InfusionLauren Appell, Liora M. Schultz, Arunkumar Modi et al.|Transplantation and Cellular Therapy|2025Cited by 0
Liberalizing hospital proximity requirements for children/young adults with low-burden B-ALL receiving tisagenlecleucelLauren Appell, Christina Baggott, Khanh Nguyen et al.|Blood Advances|2025Cited by 0